Cadrenal Therapeutics, Inc. announced that the Company is expanding its focus for tecarfarin to patients with implanted medical devices for heart diseases who are struggling with the lack of effective anticoagulant treatment options. Based on clinical data, market research, and insights from key industry experts, the Company believes this approach may be a potential additional indication for tecarfarin. Patients with implanted medical devices such as left ventricular assist devices (LVADs) struggle with warfarin due to the way in which it is metabolized, resulting in suboptimal anticoagulation.

Tecarfarin is specifically designed to solve warfarin's metabolism problem via an alternate pathway that is abundant and essentially insaturable, providing a much more reliable pharmacokinetic profile.